Literature DB >> 694843

Ticlopidine - an antiplatelet drug: effects in human volunteers.

J R O'Brien, M D Etherington, R D Shuttleworth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 694843     DOI： 10.1016/0049-3848(78)90012-9

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  10 in total

Review 1.  Platelet surface physiology and its importance in pharmacotherapy design and development: the adenosine diphosphate receptor antagonists.

Authors:  R C Becker
Journal:  J Thromb Thrombolysis       Date:  2000-08       Impact factor: 2.300

2.  Long-term low dose ticlopidine treatment in rheumatoid arthritis: effects on serum sulphydryl levels, technetium index, erythrocyte sedimentation rate, and clinical disease activity.

Authors:  M G Grimaldi
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.

Authors:  G de Gaetano; V Bertelé
Journal:  Agents Actions       Date:  1984-01

Review 4.  Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke.

Authors:  S Noble; K L Goa
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

5.  Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.

Authors:  A Aukland; R A Hurlow; A J George; J Stuart
Journal:  J Clin Pathol       Date:  1982-07       Impact factor: 3.411

6.  Metabolism of ticlopidine in rats: identification and quantitative determination of some its metabolites in plasma, urine and bile.

Authors:  A Tuong; A Bouyssou; J Paret; T G Cuong
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

Review 7.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.

Authors:  Thomas Lenz; Amy Wilson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.

Authors:  E Saltiel; A Ward
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

Review 10.  Antiplatelet drugs: clinical pharmacology and therapeutic use.

Authors:  A S Gallus
Journal:  Drugs       Date:  1979-12       Impact factor: 9.546
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.